Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Giapreza mechanism of action?

See the DrugPatentWatch profile for Giapreza

How does Giapreza work in the body?

Giapreza (angiotensin II) works by raising blood pressure through the body’s vasoconstriction pathway. It is a synthetic form of angiotensin II that binds to angiotensin II receptors on blood vessels, causing them to narrow and increasing systemic vascular resistance. That increase in resistance leads to higher blood pressure, which is the main pharmacologic goal in patients treated with Giapreza for hypotension in the clinical setting it is approved for.[1]

What receptor/pathway does Giapreza target?

Giapreza targets angiotensin II receptors, which are part of the renin-angiotensin system. By activating these receptors on vascular smooth muscle, it promotes vasoconstriction—narrowing arteries and arterioles—so blood pressure increases.[1]

What does that mean for blood pressure and circulation?

By increasing systemic vascular resistance through receptor-mediated vasoconstriction, Giapreza can improve hypotension by making it easier to generate and maintain adequate arterial pressure during shock or other settings where blood pressure is low.[1]

How is Giapreza different from fluids or other vasopressors?

Unlike volume-based support (fluids) that increases circulating volume, and unlike vasopressors that act through other receptor systems, Giapreza provides angiotensin II activity directly. Its mechanism specifically centers on the angiotensin II receptor-driven vasoconstriction that raises systemic vascular resistance and blood pressure.[1]

What side effects can be explained by its mechanism?

Because Giapreza increases vasoconstriction and blood pressure, adverse effects related to increased vascular tone are plausible from its mechanism, including risks tied to reduced perfusion in certain vascular beds and possible ischemic events. The exact risk profile depends on patient factors and dosing, but the underlying driver is its receptor-mediated increase in vascular resistance.[1]

Sources
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/



Other Questions About Giapreza :

Patent litigation giapreza? Patent litigation giapreza?